What factors affect the survival of children and young people with high-risk acute lymphoblastic leukaemia?
Finding out what makes ALL more high-risk, such as age of diagnosis or type of initial treatment.
Stopping drug resistant processes in T-cell acute lymphoblastic leukaemia
Developing a test to select patients who can be treated with a new medicine that prevents steroid resistance.
Blocking processes which keep leukaemia cells alive
Investigating the possibility of combining a medicine that blocks the process with a medicine that triggers a cell's defensive response to treat ALL.
Are regular blood and bone marrow tests helpful after childhood leukaemia?
Investigating the best follow up methods for childhood leukaemia to improve aftercare.
Precision medicines for paediatric acute myeloid leukaemia
Finding which MEK inhibitors work best for children with acute myeloid leukaemia.
Targeting proteins to fight acute myeloid leukaemia
Understanding how proteins act inside acute myeloid leukaemia cells, to find new drug targets.
A better way of delivering drugs for acute myeloid leukaemia
Testing nanoparticles as a way of getting drugs where they are needed for acute myeloid leukaemia.
Using genetics to understand why acute myeloid leukaemia cells don’t respond to treatment
Looking at the genetics of bone marrow samples to see which genes affect resistance to treatment.
Using existing drugs in a new way to treat high-risk acute lymphoblastic leukaemia
Finding drugs which target genes that drive high-risk acute lymphoblastic leukaemia.